On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely competed for a smaller biotech company — Metsera. The goal? To acquire a promising weight-loss drug developer with a focus on next-generation therapies. In the end, Pfizer emerged victorious, winning the $10 billion bidding war.
Following the announcement, Metsera's shares plummeted by 14.8%, reflecting market reaction to the deal. The biotech, valued at approximately $5.44 billion and specialising in obesity-focused treatments, also sidestepped potential antitrust concerns from the Federal Trade Commission.
